October 1, 2013
Dr. Catherine Ovitt Accepted to the 2013 Mid-Career Women Faculty Professional Development Seminar
Dr. Catherine Ovitt has been accepted to the 2013 Mid-Career Women Faculty Professional Development Seminar to be held in Austin, TX in mid December. This three and a half-day seminar is primarily designed for women physicians and scientists holding medical school appointments at the Associate Professor level, and holding leadership positions within their discipline, department or institution. Seminar faculty members are chosen from various schools in the US and Canada for their demonstrated leadership abilities and offer knowledge, inspiration and valuable career advice to participants.
September 17, 2013
Mark Noble, Ph.D.
A team from the University of Rochester Medical Center has shown scientifically what many women report anecdotally: that the breast cancer drug tamoxifen is toxic to cells of the brain and central nervous system, producing mental fogginess similar to
However, in the Journal of Neuroscience, researchers also report they've discovered an existing drug compound that appears to counteract or rescue brain cells from the adverse effects of the breast cancer drug.
Corresponding author Mark Noble, Ph.D., professor of Biomedical Genetics and director of the UR Stem Cell and Regenerative Medicine Institute, said it's exciting to potentially be able to prevent a toxic reaction to one of the oldest and most widely used breast cancer medications on the market. Although tamoxifen is more easily tolerated compared to most cancer treatments, it nonetheless produces troubling side effects in a subset of the large number of people who take it.
June 27, 2013
Drs. Catherine Ovitt & Szilvia Arany's article,
Nanoparticle-mediated gene silencing confers radioprotection to salivary glands in vivojournal Molecular Therapy, has been featured on NIDCR website. The results of the study suggest that optimization of in vivo siRNA-mediated silencing for clinical application could be an effective means of protecting salivary glands in the radiation treatment of head and neck cancer. They also pointed out that the approach has significant advantages over alternative methods, as it is limited to the salivary glands, does not involve viruses, and the block in Pkcδ protein expression is only temporary.
June 19, 2013
Above is Part 3 of ISSCR's video blogs from the 2013 ISSCR annual meeting. This video introduces the fascinating research in cell-based CNS repair done by Dr. Christoph Pröschel.
Dr. Pröschel’s most recent work has focused on using human glial progenitor cells to repair damage to the CNS caused by spinal cord injury. In a 2011 study published in PLoS One, Dr. Pröschel and colleagues describe how human glial precursors were able to restore motor function to spinal cord-injured rats. In our interview, Dr. Pröschel explains the difference between replacement and repair in cell-based regenerative medicine, a theme that fellow spinal cord injury researcher Dr. Aileen Anderson of UC Irvine also frequently touches on. In our video, Dr. Pröschel also has some remarks about direct lineage reprogramming.
June 3, 2013
Researchers at the University of California, San Diego School of Medicine, with colleagues at the University of Rochester Medical Center, have identified a new mechanism that appears to suppress tumor growth, opening the possibility of developing a new class of anti-cancer drugs.
Writing in this week's online Early Edition of the Proceedings of the National Academy of Sciences, Willis X. Li, PhD, a professor in the Department of Medicine at UC San Diego, reports that a particular form of a signaling protein called STAT5A stabilizes the formation of heterochromatin (a form of chromosomal DNA), which in turn suppresses the ability of cancer cells to issue instructions to multiply and grow.
Co-authors are Xiaoyu Hu, Amy Tsurumi and Hartmut Land, Department of Biomedical Genetics, University of Rochester Medical Center; Pranabananda Dutta, Jinghong Li and Jingtong Wang, Department of Medicine, UCSD.
May 1, 2013
Mark Noble, Ph.D. and doctoral student Hsing-Yu Chen studied the molecular mechanism that allows basal-like breast cancer cells to escape the secondary effects of tamoxifen, and discovered that two proteins are critical in this escape.
The research, published in the journal EMBO Molecular Medicine, shows how to exploit tamoxifen's secondary activities so that it might work on more aggressive breast cancer—a promising development for women with basal-like breast cancer, sometimes known as triple-negative disease.
April 23, 2013
Tamoxifen is a time-honored breast cancer drug used to treat millions of women with early-stage and less-aggressive disease, and now a University of Rochester Medical Center team has shown how to exploit tamoxifen's secondary activities so that it might work on more aggressive breast cancer.
The research, published in the journal EMBO Molecular Medicine, is a promising development for women with basal-like breast cancer, sometimes known as triple-negative disease. Led by doctoral student Hsing-Yu Chen and Mark Noble, Ph.D., professor of Biomedical Genetics at URMC, the team studied the molecular mechanism that allows basal-like breast cancer cells to escape the secondary effects of tamoxifen, and discovered that two proteins are critical in this escape.
For more information and details on how to apply please visit the Office for Graduate Education and Postdoctoral Affairs.